{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:47:38Z","timestamp":1762325258893,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00432-022-03979-2","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T03:03:59Z","timestamp":1647918239000},"page":"1123-1129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"149","author":[{"given":"Yuki","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-1596","authenticated-orcid":false,"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatsugu","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiko","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"issue":"24","key":"3979_CR1","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60(24):6921\u20136926","journal-title":"Cancer Res"},{"issue":"22","key":"3979_CR2","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1200\/JCO.2001.19.22.4195","volume":"19","author":"Y Becouarn","year":"2001","unstructured":"Becouarn Y, Gamelin E, Coudert B, N\u00e9grier S, Pierga JY, Raoul JL, Proven\u00e7al J, Rixe O, Krisch C, Germa C, Bekradda M, Mignard D, Mousseau M (2001) Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 19(22):4195\u20134201","journal-title":"J Clin Oncol"},{"issue":"12","key":"3979_CR3","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.ejca.2011.04.024","volume":"47","author":"SJ Clarke","year":"2011","unstructured":"Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, Jeffrey GM, Tebbutt NC, Buck M, Lowenthal RM, Boland A, Gebski V, Zalcberg J, Simes RJ (2011) Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. Eur J Cancer 47(12):1826\u20131836","journal-title":"Eur J Cancer"},{"issue":"4","key":"3979_CR4","first-page":"169","volume":"30","author":"U Graeven","year":"2007","unstructured":"Graeven U, Arnold D, Reinacher-Schick A, Heuer T, Nusch A, Porschen R, Schmiegel W (2007) A randomised phase II study of irinotecan in combination with 5-FU\/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Onkologie 30(4):169\u2013174","journal-title":"Onkologie"},{"issue":"1","key":"3979_CR5","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.clcc.2017.10.006","volume":"17","author":"H Kayhanian","year":"2018","unstructured":"Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, Gonzalez de Castro D, Shepherd S, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N (2018) Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: a retrospective matched case-control study. Clin Colorect Cancer 17(1):e69\u2013e76","journal-title":"Clin Colorect Cancer"},{"issue":"2","key":"3979_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/annonc\/mdf034","volume":"13","author":"CH KohneK\u00f6hne","year":"2002","unstructured":"KohneK\u00f6hne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Sch\u00f6ffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13(2):308\u2013317","journal-title":"Ann Oncol"},{"issue":"3","key":"3979_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00280-017-3255-3","volume":"79","author":"H Kuramochi","year":"2004","unstructured":"Kuramochi H, Ando M, Itabashi M, Nakajima G, Kawakami K, Hamano M et al (2017) Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. Cancer Chemother Pharmacol 79(3):579\u2013585","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"3979_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"H Minami","year":"2007","unstructured":"Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17(7):497\u2013504","journal-title":"Pharmacogenet Genom"},{"issue":"11","key":"3979_CR16","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","volume":"21","author":"ML Rothenberg","year":"2004","unstructured":"Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21(11):2059\u20132069","journal-title":"J Clin Oncol"},{"issue":"9582","key":"3979_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","volume":"370","author":"MT Seymour","year":"2007","unstructured":"Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ, National Cancer Research Institute Colorectal Clinical Studies Group (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370(9582):143\u2013152","journal-title":"Lancet"},{"issue":"5\u20136","key":"3979_CR9","first-page":"168","volume":"4","author":"K Shitara","year":"2011","unstructured":"Shitara K, Matsuo K, Yokota T, Takahari D, Shibata T, Ura T, Inaba Y, Yamaura H, Sato Y, Najima M, Muro K (2011) Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. Gastrointest Cancer Res 4(5\u20136):168\u2013172","journal-title":"Gastrointest Cancer Res"},{"issue":"4","key":"3979_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00432-012-1349-1","volume":"139","author":"K Shitara","year":"2013","unstructured":"Shitara K, Yuki S, Yamazaki K, Naito Y, Fukushima H, Komatsu Y, Yasui H, Takano T, Muro K (2013) Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. J Cancer Res Clin Oncol 139(4):595\u2013603","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"3979_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausov\u00e1 J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F, R. S. (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499\u2013508","journal-title":"Lancet Oncol"},{"issue":"20","key":"3979_CR12","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20):4623\u20134632","journal-title":"Cancer"},{"issue":"2","key":"3979_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229\u2013237","journal-title":"J Clin Oncol"},{"issue":"28","key":"3979_CR13","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausov\u00e1 J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499\u20133506","journal-title":"J Clin Oncol"},{"issue":"2","key":"3979_CR14","first-page":"CD008593","volume":"2016","author":"W Wulaningsih","year":"2016","unstructured":"Wulaningsih W, Wardhana A, Watkins J, Yoshuantari N, Repana D, Van Hemelrijck M (2016) Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and. Cochrane Database Syst Rev 2016(2):CD008593","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-03979-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T10:12:05Z","timestamp":1677838325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-03979-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3979"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-03979-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"29 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following conflicts of interest: YM received honorania from Takeda, Merck Bio Pharma, and Taiho. TM received honorania from Takeda, Chudai, Merck Bio Pharma, Taiho, Bayer, Eli Lilly, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono, and Bristol-myers squibb and research funding from MSD, Daiichi Sankyo, Ono, and Novartis. TO received honorania from Ono, Bristol-myers squibb, Taiho, MSD, and Eli Lilly. TN received honorania from Eli Lilly. YN received honorania from Yakult Honsha, Taiho, Eli Lilly, Daiichi Sankyo, and AstraZeneca and research funding from Ono, and Bristol-myers squibb. YN was also a part of the advisory board of Daiichi Sankyo. HB received honorania from Eli Lilly and Taiho and research funding from Ono. HT received honorania from Taiho, Chugai, Takeda, Eli Lilly, Merck Biopharma, and Yakult Honsha. SK received honorania from Bristol-myers squibb, Chugai, Merck Bio Pharma, Daiichi Sankyo, MSD, Ono, Bayer, Taiho, and Esai and research funding from Ono, Taiho, MSD, Nobelpharma, Bristol-myers squibb, Eli Lilly, and Chugai. MT received honorania from EA Pharma. KM received honorania from Ono, Chugai, Takeda, Taiho, Sanofi, Bristol-myers squibb, Eli Lilly, and Bayer; research funding from Solasia Pharma, Merck Serono, Daiichi Sankyo, Parexel International, Pfizer, MSD, Amgen, ONO, Astellas, Sanofi, Taiho, and Esai; and consulting fees from AstraZeneca, Ono, and Amgen. KM was also a part of the advisory boards of Ono, MSD, AstraZeneca, Daiichi Sankyo, and Solasia Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board (Aichi Cancer Center Hospital IRB, ref, 2020-1-339). The institutional review board approved the waiving of informed consent because of the observational retrospective study design, with an optout opportunity provided on the institution\u2019s website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent of participants was waived by the ethics committee as a substitute opt-out.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}